Abstract
gastric cancer, and underwent a surgery of endoscopic dissection (ESD) prior to our research. All participant donated 5 ml of peripheral blood after being fully informed about the details of the study. Gastric samples were collected from 45 patients for the functional analysis. The research process was in conformity with the last vision of Declaration of Helsinki., and the protocol of the study was approved by the Ethics Committee of Yantai University, All participants have already signed the informed consent after carefully explained before their inclusion in the study.
Genotyping by taqman genotyping kit
Qiagen Genomic DNA extraction kits (Valencia, CA, USA) were used to extract DNA from GC9811 cells according to protocol. Pfu Turbo DNA polymerase (Stratagene, CA, USA) was used to amplified cDNA (MET) with carefully designed primers, an allelic discrimination assay was used to assess the genotyping for the MET SNP (rs4938723).
RNA isolation and real-time PCR
TRIzol reagent (Invitrogen, California, USA) was used to extract the total RNA from tissue samples and GC9811 cells according to the manufacturer's protocol. M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) was used to perform the reverse transcribed, the ABI 7500 fast sequence detection system (Applied Biosystems, Foster, USA) containing a SYBR green fluorescent label was used to perform the realtime PCR with a mixture of 0.25 μL of the RT reaction, 1 μL of Power SYBR Green PCR Master Mix (Applied Biosystems, Foster, USA) and 3-5 pmol of each primer in optically clear 96-well plates (Corning, NY). The parameters of the thermo were carried out for 10 min at 95℃, 15 s at 95℃for 40 cycles, 60 s at 60℃and an 30 s at 72℃for extension/detection. The expression of MET mRNA and miR-481 was cal culated relative to expression level of endoge nous control β-actin. 2 -ΔΔCt method described elsewhere was used to analyze the relative quantification of CNACAC1 mRNA and miR-481. All tests were repeated in triplicate.
Cell culture and transfection
Dulbecco's modified Eagle's medium (DMEM, Invitrogen, California, USA) containing the 100 μg/mL streptomycin, 100U/mL penicillin and 20% FCS (foetal calf serum) was used to incubate the GC9811 cells at 37℃ with 5% CO 2 /95% air as described previously. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used to perform the transfection according to the manufacturer's protocol. The 2.5x10 6 GC9811 cells transfect with the siRNA against MET (siMET), miR-481 mimics, inhibitors and 1μM pooled non-targeting siRNA (siCtrl) as described before. Three independent experiments were performed.
Cell proliferation assay 3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide assay was used to perform the cell proliferation assay as described previously. GC9811 cells were incubate into 96 wells plate for 1, 2, 3, 4 or 5 days, and 20μL MTT (3-(4, 5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) (0.5 mg/mL) was added into each well, and maintained for 3 hours, acidic isopropanol with 0.04-0.1 μM HCl was used to solubilize the GC9811 cells which was converted dye (formazan). Finally the cell proliferation assay was measured based on the absorbance at 590 nm. All experiments were repeated in triplicate.
Luciferase assay
The 3'-UTR (untranslated region) of MET with the binding site of miR-481 was amplified through PCR as described before, and the PCR product was inserted into the SacI/XbaI site of pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA), and the fragment of MET-3′-UTR mutant which was constructed by mutating the seed region of the miR-481 binding site was also inserted into the same sites at the same times. The FuGENERHD transfection reagent (Promega, Madison, WI, USA) was used to cotransfect the GC9811 cells with 25 nM miR-481 mimics, 25 nM RNA mimics (negative control) (Gene Pharma, Shanghai, China) and 150 ng pmirGLO-MET-3'-UTR plasmid or pmirGLO-mut CAACNC1-3'-UTR plasmid. The Dual-GloRLuciferase Assay System (Promega, Madison,WI, USA) was used to analyze the luciferase activity 24 hours after transfection, Renilla luciferase activity /firefly luciferase activity was used as control. GLoMaxR20/20 (Promega,Madison, WI, USA) was used to analyze the luciferase activity according to manufacturer's protocol. Each test was run in triplicate. Western blot analysis After all treatment, the GC9811 cells were harvested, and ice-cold PBS (phosphate-buffered saline) was used to wash the GC9811 cells and tissue samples twice. And the RIPAII (Invitrogen, California, USA) containing complete protease inhibitor mix, 0.1% sodium dodecyl sulfate, 0.5% Na-DOC, 1% NP-40, 0.05% NaN3, 50 mM Tris (pH 7.4) and 500 mM NaCl was used to lyse the cells for half an hour, and the celluar lysates were centrifuged for 15 minutes at 15000 rpm at 4℃ to get the supernatants (total cell lysates). BCA quantification (Pierce, Thermo Fisher Scientific, Massachusetts, USA) was used to measure the equal amounts of protein. 12% SDS-PAGE (poly-acrylamide gel electrophoresis) was used to separate the protein, and the iBlot system (Invitrogen, California, USA)was used to transfer the protein to an Immobilon-P membrane (Millipore, Bedford, MA) for 2 hours (120 V). The primary antibodies mouse anti-MET (1:5000, Calbiochem, Merck, Darmstadt, Germany) and anti-β-actin (1:8000, Calbiochem, Merck, Darmstadt, Germany) was used to treat the membrane at 4℃ overnight, and then the secondary anti-rabbit antibodies conjugated to horseradish peroxidase (HRP) at 1:10000 dilution (Dako, Danish) were used to treat the membrane for another 2 hours. SuperSignal West Dura chemiluminescent kit (Pierce, Thermo Fisher Scientific, Massachusetts, USA) was used to detect the expreesion of MET protein exposed on X-ray film (Fuji, Tokyo, Japan). Three independent tests were performed.
Statistical analysis SPSS 10.0 statistical software for Windows (SPSS, IBM, Chicago, US) was used to performed the Statistical analyses as described before. The value of P less than 0.05 was considered statistically significant. Kaplan-Meier method was used to perform the univariate survival analysis, and the log-rank test was used to assess the survival differences between the groups, predictors related to survival was performed using the Cox proportional hazards model for multivariate survival analysis. Logistic regression analysis was used to determine the SNP of the genotyping.
Results

MET1 was a target of miR-34b
MET1 has been previously reported has a crucial role in maintenance of CG methylation, the expression level of which would affect the recurrence of EGC after ESD treatment. In this study, we aimed to investigate the molecular mechanism, including the potential regulator and signaling pathways of MET1, which underlies the recurrence of EGC after ESD treatment. As shown in Fig. 1 , we identified miR-34b as a potential regulator of MET1 by searching the miRNA database online (www.mirdb.org) with the "seed sequence" located within the 3'-UTR of the target gene.
Furthermore, to validate the regulatory relationship between miR-34b and MET1, we also conducted luciferase activity reporter assay in gastric cancer cells co-transfected with wild-type MET1 3'UTR constructs with different concentration of miR-34b mimics (25nM, 50nM and 100nM) and mutant-type MET1 3'UTR with miR-34b mimics (25nM, 50nM and 100nM, and only 100 nM presented). As shown in Fig. 2 , the relative luciferase activity of cells transfected with wild-type MET1 3'UTR constructs evidently down-regulated as the concentration of miR-34b mimics increased compared with the scramble control (P<0.05), exhibiting a negative regulation in a stepwise manner. On the contrary, cells carrying mutant MET1 3'UTR constructs up-regulated the comparable relative luciferase activity index when 
Expression level of miR-34b and MET1 varied in different genotype groups of rs4938723 polymorphism
To confirm rs4938723 polymorphism affected expression of miR-34b in EGC with early recurrence after ESD in different genotype groups, we evaluated the expression of miR-34b in 50 recurrence positive and recurrence negative frozen EGC tissues using quantitative reverse transcriptase PCR (qRT-PCR). As shown in Fig. 3 , the expression of miR-34b in cells carried CC (N=26) genotype was much higher compared with TT (N=6) and TC (N=13) (P<0.05), and expression of miR-34b in cells carried TC (N=13) genotype was up-regulated than TT (N=6) group (P<0.05), suggesting the presence of minor allele (C) of rs4938723 polymorphism compromised the expression of miR-34b.
Western blot analysis and real time PCR were used to study the mRNA and protein expression level of MET1 among different genotypes. As shown in Fig. 4 , both the mRNA and protein expression level of MET1 of the TT sample group were evidently higher when compared with the minor allele carrying groups, TC and CC sample groups (P<0.05), indicating the negative regulatory relationship between miR-34b and MET1. Fig. 2 . Luciferase activity reporter assay was conducted to verify MET1 as the direct target gene of miR-34b as well as to validate the regulatory relationship between miR-34b and MET1, gastric cancer cells co-transfected with wild-type MET1 3'UTR constructs with different concentration of miR-34b mimics (25nM, 50nM and 100nM) and mutant-type MET1 3'UTR (25nM, 50nM and 100nM, and only 100 nM presented). Compared with the scramble control, the relative luciferase activity of cells transfected with wild-type MET1 3'UTR constructs evidently decreased as the concentration of miR-34b mimics increased, exhibiting a negative regulation in a stepwise manner. On the contrary, cells carrying mutant MET1 3'UTR constructs exhibited comparable relative luciferase activity index when compared with the scramble controls, indicating MET1 as the direct target gene of miR-34b with the binding site located at the segment which has been mutated. 
Identification the negative regulatory relationship between MET1 and miR-34b
To further confirm the miRNA-mRNA regulatory relationship, RT-PCR was used to examine the expression level of MET mRNA and the expression of miR-34b. According 6 . We investigated the mRNA/protein expression level of MET1 of EGC cells treated with 50nM miR-34b mimics, 100nM miR-34b mimics and 100nM miR-34b inhibitors to validate the negative regulatory relationship between miR-34b and MET1, A: The MET1 protein (upper panel) of EGC cells treated with 50nM miR-34b mimics were apparently lower than the scramble control, while those of the sample group treated with 100nM miR-34b mimics were even lower than the 50nM treatment group, B: The miR-34b inhibitors treatment group showed evidently higher expression level of mRNA (lower panel) when compared with the scramble controls and the miR34b mimics treatment groups.
to the results, confirmed the negative regulatory relationship between miR-34b and MET1with the negative correlation coefficient being -0.4087, as shown in Fig. 5 .
MiR-34b inhibits the expression of MET1
To further validate the hypothesis of the negative regulatory relationship between miR-34b and MET1, we investigated the mRNA/protein expression level of MET1 of EGC cells treated with 50nM miR-34b mimics, 100nM miR-34b mimics and 100nM miR34b inhibitors. As shown in Fig. 6 , the MET1 protein (upper panel) and mRNA expression level (lower panel) of EGC cells treated with 50nM miR-34b mimics were apparently lower than the scramble control (P<0.05), while those of the sample group treated with 100nM miR-34b mimics were even lower than the 50nM treatment group (P<0.05), indicating a concentration-dependent effect of miR-34b on the expression of MET1. Meanwhile, the miR-34b inhibitors treatment group showed remarkably higher expression level of MET1 protein (upper panel) and mRNA (lower panel) when compared with the scramble controls and the miR-34b mimics treatment groups (P<0.05), validating the negative regulatory relationship between miR-34b and MET1.
MiR-34b interfered with the viability of EGC cells
MTT assay was used to perform the analysis of cell viability, we also investigated the relative viability of EGC cells when transfected with miR-34b mimics (50nM and 100nM) and miR-34b inhibitors (100nM). As shown in Fig. 7 , the viability of cells transfected with 100nM miR-34b inhibitors showed evidently higher when compared with the scramble controls (P<0.05), while the viability of cells transfected with 50nM/100nM miR-34b mimics showed comparably lower (P<0.05), indicating miR34b negatively interfered with the viability of Fig. 8 . Cox proportional hazard model analysis was used to observe the time period between the ESD treatment and the recurrence. The recurrence-free rate was significantly longer in TT than TC/CC individuals among the 100 EGC patients enrolled.
Fig. 7.
MTT assay was used to perform the analysis of the effect of miR-34b on cell viability, the viability of cells transfected with 100nM miR-34b inhibitors showed evidently higher when compared with the scramble controls, while the viability of cells transfected with 50nM/100nM miR-34b mimics showed comparably lower.
EGC cells.
MiR-34b rs4938723 polymorphism as a biomarker to predict recurrence after ESD in EGC patients
To study the association between rs4938723 located in miR-34b polymorphism and risk of recurrence in EGC patients who received ESD treatment, we enrolled 100 EGC patients to observe the time period between the ESD treatment and the recurrence using
Discussion
The incidence of early gastric cancers tends to be on the rise, and for a a lot patients who have early gastric cancer stomach cancer can be cured contributing to improvement in techniques for diagnostic surveillance [27] . Additionally, practically negligible positive rate of metastasis to lymph node has been observed in intramucosal gastric carcinomas (IGCs). Therefore, IGCs account for the majority of candidates appropriate for minimally invasive surgical procedures like endoscopic submucosal dissection (ESD). However, relapses and metastasis to regional lymph nodes and even to liver do occur in some intramucosal carcinomas which may [26] .
The main candidate for endoscopic treatment is early gastric cancer, particularly differentiated intramucosal carcinoma which is at a particularly low risk of metastasis to lymph node. Actually, that doesn't mean these tumors are in the safety zone [28] . The metastasis indeed occurs although the incidence of such cases is extremely low. As a protooncogen, MET encodes the receptor tyrosine kinase for hepatocyte growth factor (HGF). Regulated expression of MET has an effect in normal physiologic processes including wound healing and organ regeneration, and an increasing evidences demonstrate that cancers with augmented MET activity promote cell growth, prevention from apoptosis, and invasion and metastasis [29, 30] . Several studies demonstrate that a variety of biological functions including cell proliferation, survival, invasion and tumor metastasis are mediated by the activation of MET signaling pathway [30] . The activation of MET is associated with oncogenesis in a variety ofhuman cancers [31] . It is critical in the occurrence and progression of primary tumors and metastasis [32] . High MET expressions have been associated with the metastatic dissemination of tumors and unfavorable prognosis in cases with a diversity of solid tumors [33, 34] . Studies have observed the activation of MET signaling in some non small cell lung cancer (NSCLC) tumors which harbor mutations that activate EGFR [35, 36] . Furthermore, adoptive resistance to EGFR tyrosine kinase (TK) suppressants in NSCLC has been correlated with focal amplification of the MET proto-oncogene [37] .
It was turned out that MicroRNA-34(miR-34)-an evolutionarily conserved miRNA family which include miR-34a, b and c forms-is a target of p53 gene encoding a transcriptional factorwhich is associated with apoptosis pathways and growth inhibition . Abnormal expression of miR-34a and miR-34b was found to mediate a cell-cycle arrest in theG1 phase [38] . Additionally, cell proliferation and colony formation in soft agar could be inhibited by miR-34b [39] . Moreover, higher levels of miR-34a and miR-34b in human fibroblasts could result in cellular senescence [38] . In addition, in a variety of cancer with mutation of p53 tumor suppressor gene, low expression of miR-34a and miR-34b was found [40] . It is interesting that ectopic miR-34b could impact the expression of hundreds of putative target genes that are implicated in control of cell cycle and DNA damage responses including Cyclin E2, CDK4/6and Bcl-2 [19, 38] . In this study, we searched the miRNA database online (www.mirdb.org) with the "seed sequence" located within the 3'-UTR of the target gene, and then validated MET1 to be the direct gene via luciferase reporter assay system. We also established the negative regulatory relationship between miR-34b and MET1 via studying the relative luciferase activity at different concentrations of miR-34b mimics [41] .
The effect of miRNA single nucleotide polymorphisms (SNP) in medical conditions is just being identified. For instance, SNPs in miRNAs in cancer have been determined; mir125a, foundto be changedin breast cancer, exhibitsa variant allele at one SNP ofthe mature miRNA sequence that causes decrease dexpression [42, 43] .The members of miR-34 family have been defined as direct transcriptional targets of the tumor inhibitorp53 [44] . p53 -also known as the guardian of the genome-has pivotal effect in the tumor prevention and development by regulating miR-34. miR-34 plays a regulatory effect in cell cycle progression and apoptosis by binding to the 3′-untranslated region of target genes which affect their expression. Recently, it was predicted that the promoter region of pri-miR-34b (i.e., rs4938723T/C) has a potentially functional variant that impacts the GATA-X binding sites, and the polymorphism was shown to promote the sensitivity to HCC [21] . However, our currentresults suggested that miR-34b rs4938723 plays a role in prevention from gastric cancer. Several factorsmay be associated with the contradictory findings in HCC and gastric cancer. One of them is that the same polymorphism can have different effects depending on the types of cancer. In addition, the methylation of miR-34b in HCC has not been identified currently, while CpG methylation of miR-34b has been determined in a variety of human cancers such as colorectal carcinoma and gastric cancer [45, 46] . Moreover, contradictory results may be caused by differences in the levels of methylation between HCC and gastric cancer. More studies including one conducted in a large population are necessary to verify our observations [47] . Actually, many miRNAs including miR-34b have been reported to be involved in the pathogenesis of the development of gastric cancer, and MET, as one of the target gene of miR-34b, has also been reported to be play a role in the oncogenesis of the gastric cancer [48] [49] [50] [51] . In this study, we conducted real time PCR and Western blot analysis to study the mRNA and protein expression level of MET1 among different groups (TT, TC, CC) or cells treated with different concentration of miR-34b mimics/inhibitors, we found the expression of miR-34b in cells carried CC (N=26) genotype was much higher compared with TT (N=6) and TC (N=13), and both the mRNA and protein expression level of MET1 of the TT sample group were evidently higher when compared with the minor allele carrying groups, TC and CC sample groups. And the MET1 protein/mRNA expression level of EGC cells treated with 50nM miR-34b mimics were apparently lower, while those of the sample group treated with 100nM miR-34b mimics were even lower, and the miR-34b inhibitors treatment group showed remarkably higher expression level of MET1 protein /mRNA when compared with the scramble controls and the miR-34b mimics treatment groups.
Furthermore, we also investigated the relative viability of EGC cells when transfected with miR-34b mimics (50nM and 100nM) and miR-34b inhibitors (100nM) to validate miR-34b to be negatively interfering with the viability of EGC cells. And miR-34b was also recognized as a potential biomarker to predict recurrence after ESD in EGC patients via analysis upon the recurrence-free rate among different groups of EGC patients.
Conclusion
These data confirmed miR-34b rs4938723 polymorphism was also recognized as a biomarker to predict recurrence after ESD in EGC patients via analysis upon the recurrencefree rate among different genotypes of EGC patients.
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